Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 37.9% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares traded hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a market cap of C$17.42 million, a PE ratio of -10.00 and a beta of 0.20. The company has a fifty day moving average of C$0.09 and a two-hundred day moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Why Are These Companies Considered Blue Chips?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
